Recent Posts

Viela Bio’s Inebilizumab Receives Breakthrough Therapy Designation from the FDA for Treatment of Neuromyelitis Optica Spectrum Disorder

GAITHERSBURG, Md.–(BUSINESS WIRE)–Viela Bio today announced that the U.S. Food and Drug Administration (FDA) has …

Read More »

Talaris Therapeutics Announces Promising Phase 2 Data of Novel, Allogeneic Cell Therapy in Living Donor Kidney Transplant Recipients

BOSTON & LOUISVILLE, Ky.–(BUSINESS WIRE)–Talaris Therapeutics, Inc., formerly Regenerex, a privately held biotechnology company developing …

Read More »